Navigation Links
'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients
Date:3/20/2009

A campaign which will reduce mortality in patients with acute coronary syndromes has been launched today by a coalition which includes the ESC Working Group on Acute Cardiac Care and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). "Stent 4 Life" is a project designed to encourage the wider use of reperfusion therapy with percutaneous coronary interventions (PCI, with balloon angioplasty and stent) in Europe. According to a new report introducing the campaign, it is the "unpredictable bursts" in coronary artery disease which lead to sudden ischaemic death, heart attack and unstable angina, and with them a sharp increase in mortality rate to more than 10%.(1)

Indeed, new European guidelines on the management of heart attack emphasise not only speed of action but also the importance of reperfusion to restore blood flow to the heart and improve survival rates.(2)

The Stent 4 Life campaign particularly addresses treatment of a common type of classical heart attack known as STEMI (ST-segment elevation acute myocardial infarction), a reference to its appearance on an ECG. Around one-third of all acute coronary events are diagnosed as STEMI, and the greater application of PCI (to rates above 600 per million population) "would enable us to address the needs of most patients suffering from STEMI across Europe".

The report adds: "The mission of the Stent 4 Life coalition is to promote the lifesaving indications of PCI, implying that priority will be given to targeting invasive resources to those patient groups who will benefit the most. Rather than attempting to enforce top down directives, the program will rely entirely on national Interventional Working Groups and Societies. Synergy, rather than competition, with existing initiatives will be the goal."

"There is first class evidence that primary PCI for acute STEMI is now the gold standard of care," says ESC spokesperson Professor Jean Fajadet, from the Clinique Pasteur in Toulouse, France. "But what we have seen is that its use in STEMI patients varies throughout Europe. In those countries with a high rate of PCI such as Denmark, Poland, Czech Republic and the Netherlands the number of untreated patients is low. Conversely, in countries with a low use of primary PCI the number of untreated patients is high."

The Stent 4 Life campaign aims to identify those countries where the use of primary PCI can be encouraged, and thereby the quality of care improved. The basis for the campaign is a questionnaire study with local cardiac societies in Europe and an assessment of individual requirements for a national programme. The recently announced National Infarct Angioplasty Project in the UK is one such action plan.

"We are convinced that this action will be of benefit to all," says the report. "Engaging in Stent 4 Life is simply the right thing to do, and at this early stage, we trust and rely on the active involvement of the entire interventional community."

Current registry data suggest that around 20-30 per cent of all STEMI patients in Europe still receive no reperfusion therapy. However, the report suggests that adherence to the guidelines and a greater use of primary PCI could dramatically improve STEMI patient survival.


'/>"/>

Contact: ESC Press Office
press@escardio.org
0033-492-948-627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
2. Bioabsorbable stents show promise
3. Drugs Before Stents for Stable Heart Disease, Study Says
4. Researchers Report Combined Molecules in Red Wine by Far Exceed the Biological Activity of Plain Resveratrol, Consistent With the Composition of Longevinex(R)
5. Drug-Eluting Stents Show Promise for Leg Arteries
6. Promising Three-year Data: Saving Limbs With Drug-Eluting Stents
7. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
8. SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents
9. Is Bypass Truly Better than Stenting?
10. Noninvasive screening test may detect narrowing in intracranial stents
11. Volunteer work in grade schools produces persistent health benefit for older black women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: